Abstract:In this work, core–shell structured nanoparticles co‐loaded with allogeneic antigen (Ag) and immunosuppressive agent Tacrolimus (Ag@FK506‐NPs) are constructed for sequential drug release and Ag epitope‐specific recognition and deletion of recipient alloreactive T cells, which yields good antirejection effect without compromising the overall immunity in a murine fully major histocompatibility complex‐mismatched skin allograft model. Allogeneic grafts are vulnerable to the attack launched by host alloreactive T cells, which accounts primarily for allograft failure in the clinic. Conventional pharmacological intervention mainly involves broad‐acting, nonspecific immunosuppressants that provide limited protection over the graft and may cause deleterious side effects due to insufficient allospecificity. Here, core–shell structured nanoparticles co‐loaded with allogeneic antigen (Ag) and immunosuppressive agent Tacrolimus (Ag@FK506‐NPs) are constructed. Dendritic cells (DCs) pulsed with Ag@FK506‐NPs present alloantigenic epitopes on the cell surface as a bait to capture specific T cells, especially CD8+ T cells, for intercellular FK506 transfer and alloreactive T‐cell deletion. Meanwhile, DCs are maintained in an immature tolerogenic state that induces the functional inactivation of recruited T cells. Compared with free FK506, the adoptive transfer of low immunosuppressant dose (25 000‐fold lower) of Ag@FK506‐NPs pulsed DCs is enough to yield a superior antirejection effect in a major histocompatibility complex‐mismatched murine skin transplant model. Of note, due to the cell–cell communication conferred selective T‐cell suppression, the recipient mouse is able to respond to the subsequent stimulation of an irrelevant Ag, indicating that off‐target toxicity is bypassed. Overall, this work may address some of the limitations of current allograft therapeutics.

Immunosuppressive enzyme-responsive nanoparticles for enhanced accumulation in liver allograft to overcome acute rejection

Ex Vivo Anchored PD‐L1 Functionally Prevent in Vivo Renal Allograft Rejection

Inflammasome Activation Involved in Early Inflammation Reaction after Liver Transplantation.

Helper T Cell (CD4 + ) Targeted Tacrolimus Delivery Mediates Precise Suppression of Allogeneic Humoral Immunity

Improving Acute Cardiac Transplantation Rejection Therapy Using Ultrasound-Targeted FK506-loaded Microbubbles in Rats.

Bioinspired Β-Glucan Microcapsules Deliver FK506 to Lymph Nodes for Treatment of Cardiac Allograft Acute Rejection

Cell Communication‐Mediated Selective Drug Delivery for Epitope‐Specific Deletion of Alloreactive T Cells in Organ Transplant

Albumin Based Nanomedicine for Enhancing Tacrolimus Safety and Lymphatic Targeting Efficiency.

Chitosan nanoparticles encapsulated with BEZ235 prevent acute rejection in mouse heart transplantation

A novel FK506-loading mesoporous silica nanoparticle homing to lymph nodes for transplant rejection treatment

Target-oriented delivery of self-assembled immunosuppressant cocktails prolongs allogeneic orthotopic liver transplant survival

Immune Responsive Release of Tacrolimus to Overcome Organ Transplant Rejection.

Development and effects of tacrolimus-loaded nanoparticles on the inhibition of corneal allograft rejection

In Vivo Kidney Allograft Endothelial Specific Scavengers for On‐Site Inflammation Reduction under Antibody‐Mediated Rejection

Delivery of FK506-loaded PLGA Nanoparticles Prolongs Cardiac Allograft Survival.

Biomimetic Glucan Particles with Aggregation-Induced Emission Characteristics for Noninvasive Monitoring of Transplant Immune Response

Targeting peripheral immune organs with self‐assembling prodrug nanoparticles ameliorates allogeneic heart transplant rejection

Immunosuppressive effect of PLGA-FK506-NPs in treatment of acute cardiac rejection via topical subcutaneous injection

Reactive Oxygen Species Responsive Multifunctional Fusion Extracellular Nanovesicles: Prospective Treatments for Acute Heart Transplant Rejection

Novel approach for enhancing skin allograft survival by bioadhesive nanoparticles loaded with rapamycin

Rapamycin Liposomes Targeted to Lymph Nodes Inhibit Dendritic Cell Maturation for the Treatment of Transplant Rejection